These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23136196)

  • 1. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
    Jameson GS; Hamm JT; Weiss GJ; Alemany C; Anthony S; Basche M; Ramanathan RK; Borad MJ; Tibes R; Cohn A; Hinshaw I; Jotte R; Rosen LS; Hoch U; Eldon MA; Medve R; Schroeder K; White E; Von Hoff DD
    Clin Cancer Res; 2013 Jan; 19(1):268-78. PubMed ID: 23136196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
    J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.
    Alemany C
    Curr Oncol Rep; 2014 Feb; 16(2):367. PubMed ID: 24445499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
    Aggarwal C; Cohen RB; Yu E; Hwang WT; Bauml JM; Alley E; Evans TL; Langer CJ
    Clin Lung Cancer; 2018 Mar; 19(2):157-162. PubMed ID: 29129435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etirinotecan pegol for the treatment of breast cancer.
    López-Miranda E; Cortés J
    Expert Opin Pharmacother; 2016; 17(5):727-34. PubMed ID: 26881332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
    Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
    Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Rustin G; Vergote I; Micha JP; Duska LR; Reed N; Bendell J; Spitz D; Dark G; Hoch U; Tagliaferri M; Hannah AL; Garcia AA
    Gynecol Oncol; 2017 Nov; 147(2):276-282. PubMed ID: 28935273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
    Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
    Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
    [No Abstract]   [Full Text] [Related]  

  • 11. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
    Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
    Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
    Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
    Lenz HJ; Philip P; Saunders M; Kolevska T; Mukherjee K; Samuel L; Bondarde S; Dobbs T; Tagliaferri M; Hoch U; Hannah AL; Berkowitz M
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1161-1169. PubMed ID: 29043412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
    Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Dieras V; Müller V; Tagliaferri M; Hannah AL; Cortés J
    Future Oncol; 2019 Jul; 15(19):2211-2225. PubMed ID: 31074641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
    Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Diéras V; Müller V; Du Y; Currie SL; Hoch U; Tagliaferri M; Hannah AL; Cortés J;
    JAMA Oncol; 2022 Jul; 8(7):1047-1052. PubMed ID: 35552364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.
    Kümler I; Sørensen PG; Palshof J; Høgdall E; Skovrider-Ruminski W; Theile S; Fullerton A; Nielsen PG; Jensen BV; Nielsen DL
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):169-178. PubMed ID: 30406838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
    Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etirinotecan pegol: an option for late-stage breast cancer?
    Nielsen DL; Brünner N
    Lancet Oncol; 2013 Nov; 14(12):1149-51. PubMed ID: 24095297
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
    Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
    J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.
    Anthoney DA; Naik J; Macpherson IR; Crawford D; Hartley JM; Hartley JA; Saito T; Abe M; Jones K; Miwa M; Twelves C; Evans TR
    BMC Cancer; 2012 Nov; 12():536. PubMed ID: 23170896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.